<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02575547</url>
  </required_header>
  <id_info>
    <org_study_id>2015-FXY-034-Nutrition and NPC</org_study_id>
    <nct_id>NCT02575547</nct_id>
  </id_info>
  <brief_title>Effect of Chemoradiotherapy on Nutritional Status in Advanced NPC Patients</brief_title>
  <official_title>Effect of Neoadjuvant Chemotherapy Followed by Concurrent Chemo-radiotherapy on Nutritional Status in Locoregionally Advanced Nasopharyngeal Carcinoma Patients: Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhao Chong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Xiamen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Hospital of Guizhou Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hainan People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Foshan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an prospective，open-label, none-interventional, observational， multicenter phase II
      clinical trial. The purpose of this study is to observe the effect of neoadjuvant
      chemotherapy followed by concurrent chemoradiation therapy(CCRT) on nutritional status in
      locoregionally advanced nasopharyngeal carcinoma(NPC) patients, analyse the changes of
      patients' nutrition status during the treatment and the connection between nutrition changes
      and curative effects, evaluate nutritional risks under the neoadjuvant chemotherapy and CCRT
      and provide data and basis for further study。
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Body weight</measure>
    <time_frame>baseline and 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Toxicity</measure>
    <time_frame>3 months</time_frame>
    <description>To evaluate the acute toxicity with Common Terminology Criteria For Adverse Events (CTCAE) 3.0 when adjuvant chemotherapy and concurrent chemoradiation is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Laboratory Values</measure>
    <time_frame>36 months</time_frame>
    <description>To observe patients' complete blood cell count and blood biochemical examination during the treatment and three years after the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events That Are Related to Treatment</measure>
    <time_frame>36 months</time_frame>
    <description>Using European Organization for Research and Treatment of Cancer(EORTC) quality of life questionnaire(QLQ)-C30(version 3.0) and EORTC QLQ-H&amp;N35(Version 1.0) to access the quality of life. Collecting data before treatment, 1 week after each 4/5 cycles of chemotherapy, 3 years after all treatment finished.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor regressive rate after treatment</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity</measure>
    <time_frame>36 months</time_frame>
    <description>To evaluate the late toxicity with the SOMA criterion after 1/2/3 years of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Three-year locoregional relapse free survival rate</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Three-year distance metastasis free survival rate</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Three-year overall survival rate</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Three-year disease free survival rate</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">186</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <condition>Malnutrition</condition>
  <arm_group>
    <arm_group_label>NC+CCRT</arm_group_label>
    <description>Patients treated with neoadjuvant chemotherapy(NC) (cisplatin and docetaxel) and CCRT (cisplatin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin and docetaxel</intervention_name>
    <description>NC：cisplatin 75 mg/m2 intravenous infusion in day1，docetaxel 75 mg/m2 intravenous infusion in day1，both drugs are given every 3 weeks, two courses.
CCRT: intensity modulation radiation therapy(IMRT) and cisplatin (100mg/m2 on day 1) every three weeks for three\three cycles during radiation therapy(RT).
Dietary supplement: enteral nutrition and parenteral nutrition</description>
    <arm_group_label>NC+CCRT</arm_group_label>
    <other_name>radiation</other_name>
    <other_name>enteral nutrition and parenteral nutrition</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        III-IVb(Union for International Cancer Control,UICC 7th) NPC patients with histologic
        diagnosis of World Health Organization(WHO) II
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly histologic diagnosis of nasopharyngeal carcinoma(WHO II)

          -  All genders，range from 18～65 years old

          -  Karnofsky performance status(KPS) ≥ 80

          -  Clinical stage III~IVb(UICC 7th)

          -  Without significant digestive system disease，nutritional and metabolic diseases or
             endocrine disease

          -  Without significant cardiac，respiratory，kidney or liver disease

          -  Not received radiotherapy, chemotherapy and other anti-tumor treatment(including
             immunotherapy)

          -  white blood cell(WBC) count ≥ 4×109/L, neutrophile granulocyte(NE) count ≥ 1.5×109/L,
             Hemoglobin(HGB) ≥ 10g/L, platelet(PLT) count ≥ 100×109/L

          -  alanine aminotransferase (ALT) or aspartate aminotransferase(AST) ＜ 1.5×upper limit of
             normal(ULN), bilirubin ＜ 1.5×ULN, alanine aminotransferase (CCR) ≥ 30ml/min

          -  Inform consent form

        Exclusion Criteria:

          -  Distance metastases

          -  Second malignancy within 5 years

          -  Drug or alcohol addition

          -  Do not have full capacity for civil acts

          -  Active systemic infections

          -  Chronic consumptions

          -  Mental disorder

          -  Pregnancy or lactation

          -  Concurrent immunotherapy or hormone therapy for other diseases

          -  Severe complication, eg, uncontrolled hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chong Zhao, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.sysucc.org.cn</url>
    <description>Home Page of Cancer Center, Sun Yat-sen University</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2015</study_first_submitted>
  <study_first_submitted_qc>October 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2015</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhao Chong</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Nutritional Status</keyword>
  <keyword>Locoregionally Advanced Nasopharyngeal Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Malnutrition</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

